Cross-Sector entity
Antengene is most often covered alongside TCE, which appears in 2 of these 2 stories. The clearest coverage concentration is market-trends: 1 of 2 stories, with the rest divided among 1 other category. Antengene appears in 2 tracked Cross-Sector stories from March 20, 2026.
2 verified stories tracked
Last mentioned: Mar 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Antengene is most often covered alongside TCE, which appears in 2 of these 2 stories. The clearest coverage concentration is market-trends: 1 of 2 stories, with the rest divided among 1 other category. Antengene appears in 2 tracked Cross-Sector stories from March 20, 2026. The tracked stories average 3 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Antengene. Shared-story counts are live from our verified record — not editorial picks.
Profitability Target
Antengene aims to achieve its first full year of profitability.
Profitability Target
Anticipated inflection point for company-wide net profitability.
AACR 2026
Antengene scheduled to present data on next-generation ADCs and TCEs.
Earnings Release
2025 full-year results announced, highlighting first TCE out-licensing.
2025 FY Results
Company announces full-year results and confirms shift toward 2026 profitability.
UCB Partnership
Antengene enters into a global license agreement with UCB for ATG-201 for $60M upfront.
Fiscal Year End
Antengene concludes its most significant R&D year to date.
Antengene Corporation has reported its 2025 full-year financial results, highlighted by the first successful out-licensing of its proprietary T-cell engager (TCE) platform. This strategic milestone validates the company's R&D capabilities and establishes a clear path toward projected profitability by 2026.
Antengene Corporation has reported its 2025 full-year financial results, highlighted by its first T-cell engager (TCE) out-licensing agreement. This milestone validates the company's proprietary platform and establishes a clear financial trajectory toward achieving profitability by 2026.
Source: asiabulletin.com · philippinetimes.com
